Fundraising Fox
Andrew Sinclair
InvestorManaging Director, Head of Publics & Late Stage at Abingworth
London
Writes $15M – $30M checks · typically $22.5M
Find your path to Andrew
Sign up to see every warm intro you have to Andrew
- Paths you didn't know you had: your email and LinkedIn already hold routes to Andrew. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Andrew Sinclair joined Abingworth in 2008 after working as an equity analyst in the pharmaceutical and biotechnology sectors. He heads the firm's Publics and Late Stage strategies, works across CCD and private investing, and evaluates public company opportunities including VIPE investments. Before Abingworth he was a Senior Equity Analyst and Director at HSBC Global Markets covering mid-cap pharmaceuticals, and previously worked at Credit Suisse and SG Cowen. He holds a PhD in Chemistry and Genetic Engineering from the BBSRC Institute of Plant Science, Norwich, and a BSc in Microbiology from King's College London, and qualified as a chartered accountant with KPMG.
Contact· self-published, not guessed
Invests in
Biotech
Deals · 1
Verona PharmaBoard seat
via Abingworth · filed Jul 2020 · $200.2M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Adicet BioAscendcAMPfieldEntact BioHilleVaxPhathomR1 TherapeuticsSolenoTimberlyne
Investor
Ascend Gene & Cell TherapiesEntact BioR1 TherapeuticsSoleno Therapeutics
Sources: the firm's website · SEC Form D filings · curated public sources.
Colleagues at Abingworth
Network6
Investors connected to Andrew in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Andrew Sinclair?
- Andrew Sinclair joined Abingworth in 2008 after working as an equity analyst in the pharmaceutical and biotechnology sectors. He heads the firm's Publics and Late Stage strategies, works across CCD and private investing, and evaluates public company opportunities including VIPE investments. Before Abingworth he was a Senior Equity Analyst and Director at HSBC Global Markets covering mid-cap pharmaceuticals, and previously worked at Credit Suisse and SG Cowen. He holds a PhD in Chemistry and Genetic Engineering from the BBSRC Institute of Plant Science, Norwich, and a BSc in Microbiology from King's College London, and qualified as a chartered accountant with KPMG.
- Where does Andrew Sinclair work?
- Andrew Sinclair is Managing Director, Head of Publics & Late Stage at Abingworth.
- What does Andrew Sinclair invest in?
- Andrew Sinclair invests in Biotech.
- What check size does Andrew Sinclair write?
- Andrew Sinclair typically writes checks of $15M – $30M.
- What boards does Andrew Sinclair sit on?
- Andrew Sinclair holds tracked board seats at Adicet Bio, Ascend, cAMPfield, Entact Bio, HilleVax, Phathom, R1 Therapeutics, Soleno, Timberlyne, Verona Pharma.
- What companies has Andrew Sinclair invested in?
- Investments tracked here include Ascend Gene & Cell Therapies, Entact Bio, R1 Therapeutics, Soleno Therapeutics.
About this profile. Compiled from public sources — Abingworth's own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights